Efficacy and safety of pyrotinib in the treatment of HER2-positive liver metastatic advanced breast cancer
Pyrotinib-based therapy is efficacious and safe for patients with HER2-positive advanced breast cancer with liver metastases, while further large-scale clinical trials are warranted to validate these results.
Authors
- Daiqin Luo (ORCID: https://orcid.org/0000-0002-6045-3971)
- Junyuan Lv
- Yong Li (ORCID: https://orcid.org/0000-0001-7551-1137)
- Taolang Li (ORCID: https://orcid.org/0000-0001-8150-7687)
- Mingyuan He (ORCID: https://orcid.org/0000-0002-1146-616X)
- Hui Cao (ORCID: https://orcid.org/0000-0002-6775-9287)
- Xiaoming Cheng (ORCID: https://orcid.org/0000-0002-1730-4989)
- Yongxia Li (ORCID: https://orcid.org/0000-0002-6445-9705)
- Ran Li (ORCID: https://orcid.org/0000-0002-0499-6074)
- Yuyan Zheng (ORCID: https://orcid.org/0000-0002-6000-3030)
- Li Huang (ORCID: https://orcid.org/0009-0007-9170-495X)
- Yunbi Zou
- Jianying Chang
- Feiyue Yang
Institutions
- Guiyang Medical University (CN)
- Zunyi Medical University (CN)
- Guizhou Cancer Hospital (CN)
- Guizhou Aerospace Power Science & Tech (China) (CN)
- Affiliated Hospital of Guizhou Medical University (CN)
- Guizhou Provincial People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-04-08
- DOI
- https://doi.org/10.3389/fonc.2025.1527277
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00